Business Wire

PSG

16.5.2022 09:02:11 CEST | Business Wire | Pressemeddelelse

Del
Javelo slutter sig sammen med Sympa og Recruitee i en PSG Equity-understøttet HR-platform for at vise vejen inden for performance management

Javelo, som er førende inden for områderne performance management og medarbejderengagement, og som har base i Paris, annoncerer, at virksomheden har modtaget en vækstinvestering fra PSG Equity ("PSG"). PSG er et selskab, som tilvejebringer egenkapital til vækstvirksomheder, der leverer software- og teknologibaserede tjenester, for at sætte gang i disse virksomheders vækst og muligheder for at vokse i hele Europa og USA. Javelo slutter sig sammen med de PSG-understøttede virksomheder Sympa og Recruitee om at levere udstyr til HR-ledere, som står i spidsen for at digitalisere deres teams.

Med hovedkvarter i Paris har Javelo, som blev grundlagt af Anne-Sophie Vasseur, David Guillermain, Guillaume Berthault og Gautier Machelon, udviklet en robust performance management-platform, der har som mål at hjælpe virksomheder med at udvikle en stærk feedbackkultur. Javelo er siden blevet en innovatør på det europæiske performance management-område og tilbyder et bredt spektrum af udstyr lige fra værktøjer til evaluering og udviklingssamtaler til medarbejderengagement, 360-graders feedback, objektiv sporing og medarbejderundersøgelser. I dag har Javelo tre kontorer og tæller virksomheder som Transavia, Protectas, Domino's Pizza og Manpower blandt sine kunder.

Sammen vil Javelo, Sympa og Recruitee sigte mod at levere en portefølje af førende softwareudstyr til HR-teams i små, mellemstore og store virksomheder på tværs af strategisk HR, personaleledelse, medarbejderengagement, rekruttering og performance management. Med over 6.000 kunder samlet på tværs af Europa, Storbritannien og USA og med over 400 medarbejdere arbejder hver enkelt virksomhed for at udvikle løsninger til innovative HR-ledere. Kendte brands som f.eks. Red Bull Media House, Breitling, BMW og TNT har hyret Javelo, Sympa og Recruitee for at få hjælp til at finde talenter af høj kvalitet, beskytte medarbejderdata og gøre det muligt for teams at træffe bedre strategiske beslutninger.

Anne-Sophie Vasseur, CEO og medstifter af Javelo , udtaler: "At Javelo slutter sig sammen med Sympa og Recruitee markerer begyndelsen på et spændende kapitel. Vi mener, at PSG's investering blåstempler det potentiale, vores platform og team har på markedet. Derudover mener vi, at samarbejdet med Sympa og Recruitee øger vores eksisterende geografiske rækkevidde og produktfokus og vil give os mulighed for fortsat at levere topresultater til vores kunder gennem banebrydende HR-udstyr."

Edward Hughes, administrerende direktør for PSG , udtaler: "Tillykke til teamet hos Javelo med det produkt og team, de har opbygget. Der er fortsat enorme muligheder i HR-softwarevertikalen, og vi er glade for at støtte Javelo, Sympa og Recruitee på deres rejse."

De finansielle vilkår er ikke offentliggjort.

Om Sympa

Sympa har hovedkvarter i Finland og er en af de hurtigt voksende HR-leverandører i Europa og førende i Norden. Med anerkendte brands som BMW, Dustin og Byggmax blandt sine kunder sigter Sympas digitale løsning mod at gøre det muligt for HR-ledere at optimere hvert trin i ansættelsesrejsen gennem mere strømlinede HR-processer, pleje- og udviklingsveje og datadrevet strategisk beslutningstagning. sympa.com

Om Recruitee

Recruitee har hovedkvarter i Amsterdam og er en cloud-baseret udbyder af ATS-løsninger. Virksomhedens digitale software er bygget til teams for at gøre det muligt for dem at opnå bedre ansættelser – sammen. Deres løsninger dækker integrationer af jobportaler, sourcing af talenter, sporing af ansøgere, automatisering af pipeline, automatisering af planlægning, og avancerede ansættelsesanalyser. Siden starten i 2015 er Recruitee vokset til nu at servicere mere end 5.000 kunder fra over 75 lande, hvoraf størstedelen er fra virksomhedens kernemarkeder Benelux, DACH, Storbritannien og USA www.recruitee.com

Om Javelo

Javelo har kontorer i Paris, Marseille og Barcelona og er en SaaS-platform til HR-performance management. Javelo støtter innovative HR-ledere i digitalisering af praksis relateret til udviklingssamtaler, som ofte kendetegnes af uhåndterlige mængder for HR-ledelsen og ikke er videre inspirerende for folk. Virksomheden tilbyder en enkel, intuitiv platform, der har til formål at hjælpe HR-afdelinger med at optimere evalueringsprocessen og involvere alle i mere samarbejdsorienterede administrationsmilepæle, der fremmer præstationer og skaber engagement. javelo.io

Om PSG

PSG er et selskab, som tilvejebringer egenkapital, og som samarbejder med virksomheder, der leverer software- og teknologibaserede tjenester, for at hjælpe dem med at navigere i transformationsvækst, udnytte strategiske muligheder og opbygge stærke teams. Efter at have understøttet mere end 100 virksomheder og faciliteret over 400 add-on-opkøb medbringer PSG omfattende investeringserfaring, dyb ekspertise inden for software og teknologi og et stærkt engagement i at samarbejde med ledelsesteams. PSG blev grundlagt i 2014 og opererer fra kontorer i Boston, Kansas City, London, Paris, Madrid og Tel-Aviv. Du kan få mere at vide om PSG på www.psgequity.com .

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye